Back to results
US 2016/0355455 A1Published application
Compounds and methods for delivery of prostacyclin analogs
AssigneeUnited Therapeutics Corporation
InventorsKen Phares, David Mottola
Life of this patent
Estimating the term…
Abstract
This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
Claims29
A compound having structure I:
- wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
- wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2, and R3 are not H;
- an enantiomer of the compound;
- or
- a pharmaceutically acceptable salt of the compound.
2 more elements
A pharmaceutical composition comprising:
- (A) a compound having structure I:
- wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
- wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2, and R3 are not H;
- an enantiomer of the compound;
- or
- a pharmaceutically acceptable salt of the compound;
- and
- (B) a pharmaceutically acceptable excipient.
5 more elements
A method of treating pulmonary hypertension in a human subject comprising administering to a subject in need thereof an effective amount of a compound having structure I:
- wherein R1 is independently selected from the group consisting of H, substituted and unsubstituted benzyl groups, and groups wherein OR1 are substituted or unsubstituted glycolamide esters, and
- wherein R2 and R3 may be the same or different and are independently selected from the group consisting of H, phosphate and groups wherein OR2 and OR3 form esters of amino acids, with the proviso that all of R1, R2 and R3 are not H;
- an enantiomer of the compound;
- or
- a pharmaceutically acceptable salt of the compound.
2 more elements
Dependencies are inferred from the claim text.